Anagrelide capsules in the UK

Understanding essential thrombocythaemia.

Essential thrombocythaemia, often shortened to ET, is a myeloproliferative neoplasm: a bone-marrow disorder in which too many platelets are produced. Platelets take part in clotting. Diagnosis and the significance of a high platelet count need clinical assessment; a high result alone does not establish ET.

People with ET have different treatment and monitoring needs. Your haematology team explains what the condition and your results mean for you. General information cannot identify the right treatment from a platelet number.

Where anagrelide fits in specialist care.

Anagrelide is a prescription medicine used to lower platelet counts in selected patients with ET, including when current treatment is not tolerated or has not reduced the count sufficiently. Treatment is initiated by a clinician experienced in managing ET.

You may see the generic name anagrelide or a product name such as Xagrid. The prescription’s exact product, strength and directions should be checked rather than treating a product name as a new treatment recommendation.

Your care team considers the whole clinical picture. Anagrelide is one treatment option within specialist care, not a medicine to request solely because of an internet description.

The prescription and monitoring plan belong together.

The medicine leaflet describes regular blood tests and important cautions involving heart, liver and kidney health. Keep the specialist’s monitoring and review arrangements alongside the prescription routine.

If instructions change after a review, make sure the current directions reach the person issuing the prescription and the dispensing pharmacy. A previous label or medicine list may no longer reflect the current plan.

Practical questions to ask the clinic include who will issue the next prescription, who arranges monitoring and which contact route to use if supply is becoming difficult. Those responsibilities should be clear before moving a medicine between supply settings.

Important medicine-information points.

Do not stop anagrelide suddenly without speaking to your doctor. The leaflet warns that abrupt withdrawal can raise the risk of stroke. It also highlights interactions, including increased bleeding risk with aspirin, and possible serious heart-related effects.

Give your clinician and pharmacist an up-to-date list of medicines. Ask for advice about troublesome effects such as headache, nausea or palpitations. The product leaflet explains which symptoms need immediate medical attention and contains the full precautions.

For a severe or life-threatening problem, use urgent medical services rather than a routine supply email. Follow the instructions from your own clinical team.

Preparing a prescription or supply question.

Keep clinical documents and identity information out of an initial general email. The branch or specialist can arrange an appropriate route for information needed to handle the prescription.

If the usual supply route is difficult.

Ask the current dispensing pharmacy what has been checked and contact the specialist team if a gap is approaching. A community pharmacy can discuss an existing prescription, but it cannot assume responsibility for treatment initiation or hospital prescribing.

If community dispensing is appropriate, the exact item, valid prescription and current availability still need checking. An information page does not establish stock, an equivalent product or a confirmed delivery date.

Use the prescription-support guide for general enquiry steps and the delivery guide for branch-checked arrangements. Keep the haematology plan central to the conversation.

Questions patients and carers ask

Related practical reading

The condition guide discusses organising existing prescriptions and questions for the clinical team.